Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents

Chinese Medical Journal

Volumn 120, Issue 5, 2007, Pages 400-404

  Sun, Jie ^a   FU, Zhi Min ^a   Fang, Chang Qing ^a   Li, Jian Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cisplatin osteosarcoma; Doxorubicin; Methotrexate; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CELL STRUCTURE; CYTOTOXICITY; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; PHASE CONTRAST MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 33947641205     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200703010-00010     Document Type: Article

References (13)

1. Sandak VK, Bertelsen CA, Kern DH, Morton DL. Evolution and clinical application of a rapid chemosensitivity assay. Cancer 1985; 55: 1367-1371.
2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety of antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
3. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J,et al. The receptor for the cytotoxic ligand TRAIL.Science 1997; 276: 111-113.
4. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5,a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7: 821-830.
5. Nagata S. Apoptosis by death factor. Cell 1998;88:355-365.
6. Ashkenazi A, Dixit VM.Death recepters: signaling and modulation. Science 1998; 281: 1305-1308.
7. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF,et al. Cloning and characterization of TRAIL-R3,a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165-1170.
8. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD,a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett 1998;424: 41-45.
9. Marsters SA,Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003-1006.
10. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin R. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813-820.
11. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C,et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
12. Griffith TS, Chin WA,Jackson GC, Lynch DH, Kubin MZ.Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-2840
13. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells,to Apo2L/ TRAIL-induced apoptosis. Int J Cancer 2002; 99: 491-504.